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A chitosan-alginate nanoparticle system encapsulating doxorubicin (DOX) was prepared by a novel ionic gelation method using
alginate as the crosslinker. These nanoparticles were around 100 nm in size and more stable with higher positive zeta potential
and had higher % encapsulation efficiency (95%) than DOX loaded chitosan nanoparticles (DOX Csn NP) crosslinked with
sodium tripolyphosphate (STPP). FTIR spectroscopy and thermogravimetric analysis revealed successful loading of DOX. In vitro
drug release showed an initial release phase followed by slow release phase with higher cumulative release obtained with DOX
loaded chitosan-alginate nanoparticles (DOX Csn-Alg NP). The in vitro cytotoxicity of DOX released from the two nanoparticle
systems showed a notable difference on comparison with that of free DOX on the MCF-7 cell line. The SRB assay, AO/EB staining,
and fluorescence uptake study indicated that free DOX only showed dose dependent cytotoxicity, whereas both dose and time
dependency were exhibited by the two sets of NPs. While both systems show sustained release of DOX, from the cell viability plots,
DOX Csn-Alg NPs showed their superiority over DOX Csn NPs.The results obtained are useful for developing DOX Csn-Alg NPs
as a sustained release carrier system for DOX.
1. Introduction
Doxorubicin (DOX), with the trade name Adriamycin
also known as hydroxydaunorubicin and hydroxydauno-
mycin, is a drug used in cancer chemotherapy and derived
by chemical semisynthesis from a bacterial species [1]. DOX,
an anthracycline antibiotic, has been used for treatment of
leukemias, Hodgkin’s lymphoma, bladder, breast, stomach,
lung, ovarian and thyroid cancers, soft tissue sarcoma, and
multiplemyeloma [2].The clinical usage ofDOX is associated
with increased risk of cardiotoxicity which in turn leads to
congestive heart failure [3]. In order to increase the anticancer
efficacy by prolonging the circulation time in blood stream
and reduce its toxicity, different carrier systems for DOX
have been developed such as liposomes [4] and polymeric
nanoparticles [5]. The primary goal of using nanotechnology
in medicine is to develop new safety delivery systems having
reduced toxicity and biocompatibility while maintaining
therapeutic effects [6].
At present, it has become customary to use naturally
occurring polymers as source materials for drug delivery
[7]. Nanoparticles of polymers not only protect the bioactive
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material but also facilitate the control release of the material
[8]. Due to some inherent problems such as low encap-
sulation efficiency, and rapid leakage of entrapped drugs
in liposomes, usage of polymeric nanoparticles has gained
more attention over liposomes [9]. Polysaccharides of natural
origin which offer a wide diversity in their structure and
properties due to their wide range of molecular weight and
chemical composition [10] are extensively being researched
in the drug delivery field. Further, the unique properties
of polysaccharides such as nontoxicity, full biodegradability,
biocompatibility, high stability, hydrophilicity, and also the
high abundance in nature and low cost in processing will
increase their usage in synthesizing drug delivery systems
[11].
Among these naturally occurring polysaccharides, the
two chosen, chitosan and alginate, are polyelectrolyte poly-
mers of opposite charges [12]. They are very promising and
have been extensively exploited in the drug delivery field for
controlled drug release [13, 14]. Chitosan, a cationic, linear
nitrogenous polysaccharide composed of glucosamine and N
-acetyl-glucosamine linked by (1→ 4) 𝛽-glycosidic bonds, is
the second most abundant polymer in nature after cellulose
[15]. It is a hydrophilic polymer obtained from deacetylation
of aminoacetyl groups of chitin which is themain component
of the shells of crustaceans, the cell walls of the fungi, and the
cuticle of insects [16]. In addition to the main properties of
polysaccharides such as biocompatibility and biodegradabil-
ity [17], the bioadhesiveness of chitosan [18] which facilitates
the ionic interaction of positively charged amino groups
of chitosan with negatively charged mucous layer [19] is
accountable for its usage as a promising matrix in pharma-
ceutical industry. Alginate is a hydrophilic anionic copolymer
which is composed of alternating blocks of (1-4) linked 𝛽-
D-mannuronic acid (M units) and 𝛼-L-guluronic acid (G
units) obtained from natural sources such as cell walls and
intercellular spaces of marine brown algae and bacteria [19].
The wide pharmaceutical applicability of alginate depends
on its ability to form hydrogels by chelating with divalent
cations [20]. The easy gelling property of both chitosan and
alginate can be used to prepare polyelectrolyte complexes of
polycations and polyanions [21]. Chitosan-alginate polyionic
complex is formed via the ionic interactions between the
amine group of chitosan and the carboxylic group of alginate
through ionic gelation [22]. Since these interactions reduce
the porosity of the complex it protects the encapsulant and
slows the release effectively than either chitosan or alginate
alone [23]. The high solubility of chitosan in low pH is
reduced by the poor solubility of alginate network at low pH,
while alginate is stabilized at high pH by chitosan which is
less soluble at high pH [11].
In the present study, a novel carrier system for DOX
was developedwith chitosan and alginate. Several researchers
have investigated the delivery properties of chitosan-alginate
NPs and nanocomposites for a variety of drugs. Though
DOX in chitosan NPs have been investigated in various
aspects, there is no reported literature on chitosan-alginate
NP which was directly used as a delivery vehicle for DOX.
There are several reports where chitosan and alginate have
been utilized to prepare carriers to deliver DOX. In one
method, CMC-predoped porous CaCO
3
microparticles were
assembled in layered fashion by coating alternatively with
chitosan and alginate [24]. A second group had synthesized
chitosan-alginate capsules consisting of BSA in a gel capsule
for DOX delivery [25]. There is another study in which
mesoporous silica nanoparticles were coated with chitosan
and alginate to deliver DOX [26]. In the method we report,
we have only used the two biopolymers chitosan and alginate
to form nanoparticles of a very small size range using a
different method following the ionic gelation technique. A
comparison with DOX Csn NP revealed an increase in
efficiency and potency of Csn-Alg NPs over that of Csn NPs.
The cytotoxicity effect of these DOX encapsulated NPs versus
free DOX was investigated with the human breast cancer cell
line, MCF-7.
2. Materials and Methods
2.1. Materials. Chitosan (medium molecular weight, dea-
cetylation degree ∼75%), low viscosity sodium alginate,
sodium tripolyphosphate (STPP), and doxorubicin hydro-
chloride (98.0%) were purchased from Sigma-Aldrich Chem-
ical Company (St. Louis, MO, USA). All other reagents were
of analytical grade and used directly.
MCF-7 cells were purchased fromATCC,USA. Powdered
Dulbecco’s Modified Eagle Medium was purchased from
Invitrogen Life Technologies (Carlsbad, CA, USA). Fetal
bovine serum (FBS), streptomycin/penicillin, dimethyl sul-
foxide (DMSO), agarose, and trypsin/EDTA were purchased
from Sigma Aldrich Chemical Company (St. Louis, MO,
USA).
2.2. Preparation of DOX Loaded Chitosan-Alginate Nanopar-
ticles. DOX Csn-Alg NPs were prepared by a novel method.
The chitosan flakes were dissolved in 40mL of acetic acid
(0.3% v/v) and the resulting solution (2mg/mL) was adjusted
to pH 4.8. The alginate solution (1mg/mL) was prepared by
dissolving in distilled water at room temperature overnight
and adjusting the pH to 5.2. The drug DOX (30 𝜇g/mL)
was stirred with alginate solution for 24 h to form the drug-
alginate complex. The chitosan solution was stirred with
Tween 80 (0.310 g) at 60∘C for 2 h to obtain a homogeneous
mixture and this solution was gradually dropped to the
alginate-DOX complex over 1 h while stirring at a high speed.
The stirring was continued for another half an hour and
then refrigerated overnight.The nanoparticle suspension was
centrifuged at 9000 rpm for 45min to obtain the nanoparticle
pellet. Five formulations were prepared by varying chitosan
content to obtain different weight ratios of chitosan to
alginate of 0.5 : 1, 0.6 : 1, 0.8 : 1, 1 : 1, and 2 : 1.
For the comparison, DOX Csn NP was prepared accord-
ing to a method modified in literature [27] employing a
two-step method, that is, oil in water emulsion followed by
crosslinking.
2.3. Characterisation of DOX Loaded Nanoparticles. The
average particle size and size polydispersity of the NPs dis-
persed in water were determined by dynamic light scattering
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technique at 25∘C using a particle size analyzer (Zetasizer
Nano ZS, Malvern Instruments, UK) at a fixed scattering
angle of 90∘.The zeta potential of nanoparticles wasmeasured
using the zeta potential analyzer (ZetasizerNanoZS,Malvern
Instruments, UK). All measurements were performed in
triplicate. Fourier Transform Infrared (FTIR) spectra of
chitosan, sodium alginate, unloaded nanoparticles, andDOX
loaded NPs were obtained with a Bruker Vertex 80 IR spec-
trometer (Germany) at a resolution of 4 cm−1 from 4000 to
400 cm−1. Thermal decomposition of chitosan, sodium algi-
nate, unloaded nanoparticles, andDOX loaded nanoparticles
were analyzed using a SDTQ600 thermogravimetric analyzer
(TA Instruments, USA) from 25∘C to 800∘Cusing a ramp rate
of 10∘C/min in air. Nanoparticle morphology was examined
by electron microscopy. For scanning electron microscopy,
a drop of the particle suspension was placed on a cleaned
stub and dried overnight and imaging was done followed
by gold sputtering to the specimen by the scanning electron
microscope (SEM, SU6600, Hitachi, Japan) operating at 5
and 10 kV. Further the morphology was recorded by high-
resolution transmission electronmicroscopy (HR-TEM, JEM
2100, JEOL, Japan) operated at accelerating voltage 200 kV.
The samples prior to their analysis were placed on carbon
coated copper grids and dried under ambient conditions.
2.4. Determination of % Encapsulation Efficiency. The
amount of incorporated DOX in the NPs was determined
by measuring the fluorescent absorbance of DOX remaining
in the supernatant (free DOX) after centrifugation of
the nanoparticle mixture using a fluorometer (Fluorolog,
Horiba, Japan) with a slit width of 5 nm and excitation and
emission wavelengths at 468 nm and 550 nm, respectively.
A calibration curve was performed with a series of
concentrations to obtain the unknown DOX concentrations.
The percent encapsulation efficiency (% EE) was calculated
as follows:
% EE = Total DOX − Free DOX
Total DOX
× 100. (1)
2.5. Evaluation of In Vitro DOX Release. The release char-
acteristics of DOX from polymeric NPs were studied in
distilled water and phosphate buffered saline solution (PBS)
(pH ∼ 7.4).The centrifuged nanoparticle pellet was dispersed
in 5mL of PBS at pH 7.4 and trapped inside a dialysis
membrane (cutoff molecular weight 3.5 kDa) and immersed
in 25mL PBS. The temperature of the setup was maintained
at 37∘C in the dark with mild agitation. Aliquots (3mL)
were withdrawn at predetermined time intervals and the
fluorescence emission spectrum was recorded as described
previously. The release medium was refreshed with 3mL
of medium after each withdrawal. The release experiments
were repeated three times and average data were reported.
Using the calibration curve the unknown concentrations
were calculated; hence the cumulative release of DOX was
determined.
2.6. Cell Culture and In Vitro Cytotoxicity Studies. The
cytotoxicity activities of DOX Csn and DOX Csn-Alg NPs
against MCF-7 cells were compared to free DOX. MCF-
7 cells were grown in monolayer cultures in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10%
fetal bovine serum and 50 IU/mL penicillin and 50𝜇g/mL
streptomycin. Cells were maintained at 37∘C in 95% air/5%
CO
2
atmosphere, with 95% humidity. Culture medium was
changed every 2-3 days. Next, the cells in exponential growth
were removed by trypsinization and seeded at 5 × 103 cells
per well into a 96-well plate and incubated for 24 h for
attachment. After the incubation period, cells were exposed
to both DOX loaded NPs (DOX concentration of 0.01, 0.02,
0.05, 1.0, 4.0, and 8.0 𝜇g/mL) and to free DOX with similar
concentrations for 24, 48, and 72 h after incubation.
Cell viability was assessed by sulforhodamine B (SRB)
assay [28] and the results were expressed as a percentage of
control values. All the assays were performed in triplicate in
three different experiments.
2.7. Morphological Observation and Apoptosis Induced by
DOX Loaded Nanoparticles. Apoptosis was identified mor-
phologically by acridine orange/ethidium bromide (AO/EB)
staining. MCF-7 cells were seeded separately in 24-well plates
at 5 × 104 cellsmL−1 on cell culture treated coverslips for
24 h in a humidified atmosphere at 37∘C in 5% CO
2
to allow
cell adherence. Cells were then treated with both types of
DOX loaded NPs (DOX concentration of 0.01, 1.00, and
8.00 𝜇g/mL) and free DOX (0.01, 1.00, and 8.00 𝜇g/mL).
Treated cells were incubated for 24, 48, and 72 h and, at
the end of each incubation process, cells on the coverslips
were observed under an inverted phase contrast microscope
(Olympus CKX41SF, Japan) for morphological changes. Cells
were then fixed with 4% formaldehyde in PBS at room
temperature for 15min. Cocktail of acridine orange-ethidium
bromide (AO/EB) dyes in PBS, containing 50mgmL−1 each,
was added to the fixed cells on coverslips and incubated
for 10min at room temperature in the dark. Cells were
then visualized under a fluorescence microscope (Olympus,
BX51TRF, Japan). Both assays were performed in triplicate in
three different experiments.
2.8. Cellular Uptake of Nanoparticles. MCF-7 cells were
seeded separately in 24-well plates at 5 × 104 cellsmL−1 on
coverslips for 24 h in a humidified atmosphere at 37∘C in 5%
CO
2
to allow cell adherence. Cells were then treatedwith both
DOX loaded NP systems (DOX concentration of 0.01, 1.00,
and 8.00 𝜇g/mL) and free DOX (0.01, 1.00, and 8.00 𝜇g/mL).
Treated cells were incubated for 30min and 2 and 24 h and
at the end of each incubation process cells were rinsed twice
with PBS and then fixed with 4% formaldehyde in PBS at
room temperature for 15mins. The cells on the coverslips
were observed under the fluorescence microscope (Olympus
BX51TRF, Japan).
3. Results and Discussion
The main effort of this work was to develop a nanodelivery
system for the drug DOX using natural, biodegradable, bio-
compatible polysaccharides specially chitosan and alginate.
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Table 1: The size, zeta potential, and % EE of DOX Csn and DOX Csn-Alg NPs. All analyses were performed using the DOX loaded NPs
prepared by using optimized formulations (chitosan : STTP 2 : 1 and chitosan : alginate 2 : 1).
System Average size/nm Zeta potential/mV % Encapsulation efficiency Polydispersity index
DOX Csn NPs 100 ± 27 26 ± 3 65 ± 4 0.391 ± 0.048
DOX Csn-Alg NPs 100 ± 35 35 ± 4 95 ± 4 0.402 ± 0.071
Csn NPs 100 ± 25 30 ± 5 — 0.352 ± 0.046
Csn-Alg NPs 100 ± 28 36 ± 3 — 0.414 ± 0.065
The feasibility of using Csn-Alg NPs as a delivery system for
DOX was evaluated with comparison to DOX Csn NPs.
3.1. Formation of DOX Loaded Polymeric Nanoparticles. The
chitosan NPs are easily formed by the gelation with STPP
via electrostatic interactions. At a pH around 4.8 the pro-
tonated amino groups of chitosan interact electrostatically
with negatively charged phosphate groups of STPP [29].
The uncertainty of this encapsulation was the complexation
of DOX into the positively charged chitosan since DOX
also exhibits a positive charge. However, 65% of DOX was
encapsulated into Csn NPs in this experiment, overcoming
the charge repulsion. Since Csn NPs have shown positive
results for the DOX delivery, an effort was taken to improve
the DOX delivery with the use of alginate polymer as well.
The polyelectrolyte complex Csn-AlgNPswas prepared using
a novel method. Initially, the chitosan droplet formation
occurred with the stirring with Tween 80, followed by the
droplet solidification by ionically crosslinking of the alginate
solution. In aqueous solutions, at pH around 4 to 5.5 the
amine groups on chitosan became easily positively charged.
Alginate, on the other hand, dissolved in a neutral pH solu-
tionwhere the carboxylate groupswere negatively charged. In
aqueous solutions with pH around 5.2 chitosan amino groups
interacted with alginate carboxylate groups to form the
hydrogel. Since alginate is a negatively charged polymer the
positively chargedDOXwas complexed initially with alginate
to obtain a higher loading of the drug to the nanoparticle.The
formulation, (chitosan : sodium alginate, 2 : 1), which gave
an opalescent suspension with a positive zeta potential, was
selected as the optimum ratio for the DOX encapsulation.
This formulation resulted in 95% encapsulation efficiency of
DOX.
3.2. Shape, Size, and Surface Charge of Doxorubicin Loaded
Nanoparticles. The morphology of the polymeric NPs was
observed by scanning electronmicroscope and Transmission
Electron Microscope and both NPs were below 20 nm and
spherical in shape (Figures 1 and 2). Further, the TEM images
clearly showed the well separated, well dispersed particles.
After loading of DOX, there was no noticeable change either
in the shape or in the size in SEM and TEM images of
both NPs. In a study on carvacrol-loaded chitosan NPs,
Keawchaoon andYoksan have reportedTEM images showing
40–80 nm sized NPs [27]. In a previous study done by Liu et
al., the particle sizes of Csn-Alg NPs obtained from the trans-
mission electron microscopy (TEM) were 20–50 nm [11].
A study by Motwani et al. had shown the particle sizes
of Csn-Alg NPs obtained from TEM to be around 63 nm
[22]. Thus, using the above-mentioned method we were able
to obtain much smaller Csn-Alg NPs. The sizes obtained
from DLS technique were larger (∼100 nm, Table 1) than the
sizes obtained from SEM and TEM since DLS measures the
hydrodynamic diameter. Also the larger particle sizemight be
due to the swellability of polymeric hydrogels in the solution
[30] whereas electron microscopy shows the images of dried
particles.
The zeta potentials of both DOX Csn and DOX Csn-
Alg NPs show large positive values reflecting the stability of
the colloidal suspensions (Table 1). Having positively charged
surfaces is an added advantage when using NPs in drug
delivery since they are able to transfer easily through negative
channels in the cell membrane. An increased zeta potential
value with DOX Csn-Alg NPs, when compared to the DOX
Csn NPs, was caused by the higher amount of positively
charged DOX encapsulation with Csn-Alg NPs than that
with Csn NPs. Neutralization of the charge on chitosan by
the strong negative charge of STTP versus alginate at the
working pH may have also contributed to the differences in
zeta potential.
3.3. Characterisation of DOX Loaded Nanoparticles. The
successful loading of DOX into the polymeric NPs was
confirmed by FTIR and TGA techniques. Chemical struc-
tures of both reactants and products were analyzed by FTIR
spectroscopy. In the spectra of pure chitosan (Figure 3(b)),
characteristic peaks at 3449 cm−1 for –NH
2
and –OH stretch-
ing, 1659 cm−1 for –CO stretching, and 1596 cm−1 for –NH
2
bending vibrations were observed. Crosslinking of the amine
group of chitosan with phosphate group of STPP depicts
a clear shift in the peak at 3565 cm−1 for –NH
2
and –OH
stretching as shown in the spectrum of CsnNPs (Figure 3(c)).
On loadingDOX intoCsnNPs, the FTIR spectra (Figure 3(e))
show peak shifts resulting from hydrogen bonding in the
above modes, that is, 3578 cm−1 for –NH
2
and –OH stretch-
ing, 1685 cm−1 for –CO stretching, and 1578 cm−1 for –NH
2
bending vibrations reflecting the successful loading of DOX
into the Csn NPs.
In the spectra of pure chitosan the major vibrations of
–NH
2
and –OH stretching peak appearing at 3449 cm−1 had
shifted to 3565 cm−1 in the spectra of Csn-Alg NPs and
the –CO stretching vibration at 1659 cm−1 in pure chitosan
had also shifted to 1651 cm−1 after interaction of the amine
group of chitosan with the carboxylic group of alginate
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Figure 1: (a) Scanning electron microscopy image of Csn NP. (b) Transmission electron microscopy image of Csn NP.
(a) (b)
Figure 2: (a) Scanning electron microscopy image of Csn-Alg NP. (b) Transmission electron microscopy image of Csn-Alg NP.
(Figure 3(d)). Further, the –NH
2
bending peak at 1596 cm−1
disappeared due to binding with alginate to form the NP.
After loading DOX into the Csn-Alg NPs, the –NH
2
and
–OH stretching peak at 3565 cm−1 and the –CO stretching
vibration at 1660 cm−1 shifted to 3356 cm−1 and to 1637 cm−1,
respectively. Further, the appearance of a small peak at
1542 cm−1 for –NH
2
bending, after loading the DOX, may
reflect the physical entrapment of DOX into the Csn-Alg NPs
(Figure 3(f)).
3.4. Thermal Behaviour of DOX Loaded Polymeric Nanopar-
ticles. Nanoparticles with and without DOX were analyzed
by thermogravimetry to further evaluate the thermal stability
and successful loading of DOX. In the thermogram of
chitosan NPs, a major one-step mass loss about 40% of total
weight was observed at a peaking temperature (inflection
point temperature) of 216∘C (Figure 4). Heating up to 800∘C
retained 35% of the weight of the nanoparticles from the
residual sodium ions of the STPP crosslinked Csn NPs.
Similarly, in DOX loaded chitosan nanoparticles a 50%
weight loss from 100–400∘C was observed in two steps due
to the combined decomposition of chitosan and DOX but
the peaking temperature of 30% weight loss had shifted
to 225∘C proving the loading of the DOX into chitosan
nanoparticles (Figure 4). A new peak with 12% weight loss
in the temperature range 600–700∘C was observed with the
DOXCsnNPs showing entrapment of DOX into the polymer
matrix.
The decomposition of unloaded Csn-Alg NPs had two
major and two minor weight losses (Figure 4). The ther-
mogram of DOX loaded NPs showed the same pattern of
weight loss as the unloaded particles. However, when the
temperature reached 350∘C, 60% of weight loss was observed
with DOX loaded nanoparticles due to the decomposition
of DOX complexed nanoparticles, whereas it was only 50%
with unloaded nanoparticles. Further, the inflection point
temperature of the second major step of weight loss of
unloaded composite in the range of 600–750∘C peaked at
703∘C, whereas in the DOX loaded nanocomposite it peaked
at 750∘C reflecting the strong physical entrapment of DOX
into the nanoparticles.
3.5. In Vitro Release Kinetics of DOX from Polymeric
Nanoparticles. The in vitro release profiles of both optimized
formulations in phosphate buffered saline (PBS) solution
(pH-7.4) are shown in Figure 5. An initial burst release of
DOX from both NPs in PBS solution can be observed up
to 24 h. This accounts for about 40% of DOX from the total
encapsulated amount. Then, it followed a more gradual and
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Figure 3: FTIR spectra of (a) pure alginate, (b) pure chitosan, (c)
CsnNPprepared using 2 : 1weight ratio of chitosan to STPP, (d)Csn-
Alg NP prepared using 2 : 1 weight ratio of chitosan to alginate (e)
DOX Csn NP, and (f) DOX Csn-Alg NP.
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Figure 4: TGA thermograms of Csn NP, DOX Csn NP prepared
using 2 : 1 weight ratio of chitosan to STPP and Csn-Alg NP, and
DOX Csn-Alg NP prepared using 2 : 1 weight ratio of chitosan to
alginate.
sustained release phase for the next 72 h. Both profiles had
followed the same pattern of release but the amounts were
different. The total amount of drug released from Csn-Alg
NPs was around 60%. In contrast, the total amount of drug
released from Csn NPs was around 45%.These results clearly
indicated that the release of DOX was retarded significantly
due to the encapsulation in nanoparticles.
3.6. In Vitro Cytotoxicity of DOX Loaded Polymeric Nanopar-
ticle. Dose response curves were plotted for 3 formulations,
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Figure 5: Cumulative release of DOX from (a) DOX Csn-Alg and
(b) DOXCsnNP at preselected time intervals in pH 7.4 PBS. Results
were reported as mean ± SD, 𝑛 = 3.
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Figure 6: Cytotoxicity of free DOX, DOX Csn-Alg NP, and DOX
Csn NP against MCF-7 cells after e24 ◼48 and 󳵳72 hours of
treatments. Cell survival was assessed via SRB assay. Results were
reported as mean ± SD, 𝑛 = 4.
free DOX, DOX Csn-Alg NPs, and DOX Csn NPs (Figure 6).
Each experimental curve represents the average of a series
of 3 experiments. With free DOX, the inhibition of MCF-7
cell proliferation completely depends on the dose of the
drug used. After 48 and 72 h, 50% cell viability could not be
observed even at the lowest concentration (0.01𝜇g/mL) of
free DOX, proving the reduced effect of free DOX after 24 h;
that is, the free DOX has dose dependent cytotoxicity; thus it
might damage the normal cells during therapy, whereas the
current work demonstrated the dose-dependence as well as
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Figure 7: Morphological changes of apoptosis in MCF-7 cells observed under inverted light microscopy exposed to different concentrations
of free DOX, DOX Csn-Alg NP, and DOX Csn NP after 24 h, 48 h, and 72 h after incubation.
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Figure 8: Fluorescence microscopic observations of MCF-7 cells treated with different concentrations of free DOX, DOX Csn-Alg NP, and
DOX Csn NP stained with AO/EB after 24 h, 48 h, and 72 h after incubation.
Journal of Nanomaterials 9
Free DOX
Control
Control
Control
DOX Csn NPDOX Csn-Alg NP
0.01 𝜇g/mL
1.00 𝜇g/mL
8.00 𝜇g/mL
0.01 𝜇g/mL
1.00 𝜇g/mL
8.00 𝜇g/mL
0.01 𝜇g/mL
1.00 𝜇g/mL
8.00 𝜇g/mL
30min
24 h
2 h
Figure 9: Fluorescence microscopic observations of cellular uptake of MCF-7 cells treated with different concentrations of free DOX, DOX
Csn-Alg NP, and DOX Csn NP after 30min, 2 h, and 24 h after incubation.
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the time dependence cytotoxicity of DOX loaded NPs with
MCF-7 cell line. None of the concentrations of DOX in both
NPs that were used caused 50% inhibition of cell growth
at 24 h reflecting the slow release from NPs. Hence, during
the first 24 h, those NPs are capable of circulating in the
blood and accumulating at tumour sites before starting their
cytotoxic effect. Thus, DOX encapsulated in NPs achieve its
cytotoxicity with time; that is, there is an effect of both time
and dose on the inhibition of cell proliferation. Therefore,
this result clearly indicated that the release of DOX was
retarded significantly by the encapsulation in NPs. When
comparing the two delivery systems, the cytotoxicity effect
of DOX Csn NPs was consistently lower than that of DOX
Csn-Alg NPs (Figure 6).This is in accordance with the results
of in vitro release of DOX being higher from Csn-Alg NPs
than from Csn NPs after 72 h (Figure 5). However, both
DOX loaded systems exhibited similar behaviour with the
MCF-7 cell line (Figure 6). Same concentration of DOX
when encapsulated in NPs behaves differently than in the
free state; that is, encapsulated DOX releases slowly and
gradually increases the concentration in the medium. Hence,
it proves that encapsulating DOX in either system has
improved the efficacy of DOX over free DOX. A similar
study of doxorubicin loaded magnetic NPs grafted to smart
copolymers showed that free DOX has dose dependent but
not time dependent cytotoxicity but DOX loaded magnetic
NPs have time dependent cytotoxicity [31].
Inverted phase contrast microscopy was used for mor-
phological analysis of MCF-7 cells for observation of apop-
tosis induced by the DOX loaded NPs and free DOX.
These characteristicmorphological changes of apoptosis with
time and dose in MCF-7 cells on treatment after 24, 48,
and 72 h (Figure 7) were clearly visualized. Exposure to
free DOX clearly showed a higher cell confluence at low
doses while higher concentration of free DOX decreased cell
confluence and showed a higher proportion of rounded cells
resulting from detached cells from the culture monolayer.
Within the first 24 h, most of the cells were damaged by
the induced cytotoxicity of free DOX reflecting its dose
dependent cytotoxicity. On the other hand, bothDOX loaded
systems showed disappearance of the high cell confluence
with the dose of the drug and with time (Figure 7). This
observation is further confirmed by the fluorescence micro-
scopic results of AO/EB stained MCF-7 cells after 24, 48,
and 72 h of incubation, following the treatment with different
concentrations of freeDOXandwith the same concentrations
loaded in Csn and Csn-Alg NPs. Nuclei of viable cells were
stained uniformly bright green by AO while the apoptotic
cells exhibited yellow to orange coloration depending on the
degree of loss of membrane integrity, due to costaining with
EB (Figure 8). Early apoptotic cells have greenish yellow
nuclei while late apoptotic cells have orange to red nuclei
with condensed or fragmented chromatin (Figure 8). These
figures clearly displayed the difference in behaviour of DOX
when encapsulated in NPs. Free DOX has a dose dependent
increase in induction of apoptosis (Figure 8-24 h). Both the
dose and time dependency of DOX encapsulated in NPs are
evident from the alterations in cell staining in all the three
series (Figure 8). In the case of DOX loadedNPs, the drug has
to be released slowly from theNPs before it can exert an effect
on the cancer cells, but free DOX has an immediate effect
on the cells since it has direct contact with the cells initially.
The mechanism of action of apoptosis of DOX loaded in
NPs was not significantly different from that of the free DOX
indicating that the encapsulation of DOX in NPs does not
make any changes to its mechanism of action of apoptosis.
3.7. Cellular Uptake of Nanoparticles. DOX is a fluorescence
active compound, having a bright red color. The red color
indicates the cellular uptake of DOX when compared to the
untreated cells or cells with no internalized DOX. Internal-
ization of DOX in cancer cells was evaluated on MCF-7 cells
at different time intervals and different concentrations of
free and encapsulated DOX. Within 30min of incubation,
all concentrations of free DOX were localized within the cell
nucleus (Figure 9, 30min), whereas the localization of DOX
in NPs could be visualized depending on the concentration
and on time (Figure 9). The efficient uptake of the NPs could
be facilitated by the positive surface charge of the NPs. A
similar observationwas notedwith the in vitro cellular uptake
of paclitaxel loaded PEGylated PLGA-based NPs [32]. In
general, NPs are nonspecifically internalized into cells via
endocytosis or phagocytosis while free DOXdiffuses through
the cell membrane [33].
Morphology analysis suggests that the process of cell
growth inhibition by DOX loaded in NPs occurs over a much
longer time than by the free DOX. From these observations it
could be inferred that the DOX in NPs sufficiently associates
with the cells with time.
4. Conclusion
This study was made to assess the usefulness of the Csn-
Alg NP system as a delivery agent for the anticancer drug
DOX. Comparison with DOX Csn NPs indicated that Csn-
Alg NPs were more efficient at entrapment of DOX than the
CsnNPs.This successful loadingwas confirmedby both FTIR
and TGA data. Both nanoparticles were less than 100 nm in
size with positive zeta potentials. The in vitro release profiles
observed for these NPs were characterized by a burst initial
release followed by a more gradual and sustained release
phase. The in vitro cytotoxicity studies demonstrated that
DOX loaded NPs have potent antigrowth effect on MCF-7
cells and inhibited its cell growth, in a dose and time depen-
dent manner. Further, the observed cell apoptosis induced by
these DOX loaded NPs by phase contrast microscopy and
fluorescence microscopy after AO/EB staining proved that
there is no significant change in the mechanism of action of
DOX after encapsulating in NPs and reflect the slow release
of DOX from the NPs. According to the cytotoxicity results,
DOX Csn-Alg NPs are more cytotoxic than DOX Csn NPs.
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